Narcolepsy Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy); By Product; By Region; Segment Forecast, 2023 - 2032

Narcolepsy Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy); By Product; By Region; Segment Forecast, 2023 - 2032

The global narcolepsy therapeutics market size is expected treach USD 7.75 billion by 2032, according ta new study by Polaris Market Research. The report “Narcolepsy Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (Cataplexy, Narcolepsy without Cataplexy, Secondary Narcolepsy); By Product; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.

Narcolepsy therapeutics market is driven by several factors, including increasing awareness and diagnosis of narcolepsy, the availability of effective treatments, and the development of new medications, drive market growth. Treatments for narcolepsy include stimulants tpromote wakefulness, sodium oxybate timprove nighttime sleep and reduce cataplexy, and antidepressants tmanage cataplexy and other symptoms.

Recent developments in the narcolepsy therapeutics market, such as the approval of new medications and formulations, the acquisition of existing drugs by companies, and the ongoing research and development of new treatments, are expected tdrive market growth.

For example, the approval of Xywav (calcium, magnesium, potassium, and sodium oxybates) and Wakix (pitolisant) by the U.S. Food and Drug Administration (FDA) in 2020, and the acquisition of Sunosi (solriamfetol) by Axsome Therapeutics Inc. in 2021, are expected tincrease the availability of effective treatments for narcolepsy.

The increasing use of telemedicine and digital health technologies timprove access thealthcare and support remote monitoring and management of patients with narcolepsy is expected tfurther drive market growth.

Narcolepsy Therapeutics Market Report Highlights

cataplexy segment is expected tdominate the narcolepsy therapeutics market over the forecast period due tincrease in the demand for cataplexy treatment and increased prevalence of the narcolepsy.

Sodium Oxybate segment held a largest market share and will continue the dominance over the forecast period, due ta most commonly prescribed medicine for the cataplexy treatment.

North America dominates the global market due tthe prevalence of the narcolepsy is highest in this region and FDA has approved several medications for the treatment of narcolepsy.

The global key market players include Addrenex Pharmaceuticals, Cephalon, Inc., Arena Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc., BIOPROJET, Inc., Evotec AG, Graymark Healthcare, Inc., Hypnion, Inc., Jazz Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

Polaris Market Research has segmented the Narcolepsy Therapeutics market report based on type, product, and region:

Narcolepsy Therapeutics, Type Outlook (Revenue - USD Billion, 2019 - 2032)

Cataplexy

Narcolepsy without Cataplexy

Secondary Narcolepsy

Narcolepsy Therapeutics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

Sodium Oxybate

Central Nervous System Stimulants

Selective Serotonin Reuptake Inhibitor

Tricyclic Antidepressants

Narcolepsy Therapeutics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa